April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Intravenous Corticosteroid Treatment In Endothelial Corneal Allograft Rejection: Efficacy And Safety
Author Affiliations & Notes
  • Adriano J. Carpizo
    cornea, Fundacion Hospital Nuestra Senora de la Luz I.A.P, mexico city, Mexico
  • Alejandro Babayan-Sosa
    cornea, Fundacion Hospital Nuestra Senora de la Luz I.A.P, mexico city, Mexico
  • Oscar Baca-Lozada
    cornea, Fundacion Hospital Nuestra Senora de la Luz I.A.P, mexico city, Mexico
  • Oscar Fernandez-Vizcaya
    cornea, Fundacion Hospital Nuestra Senora de la Luz I.A.P, mexico city, Mexico
  • Simon Romano-Bucay
    cornea, Fundacion Hospital Nuestra Senora de la Luz I.A.P, mexico city, Mexico
  • Regina Velasco-Ramos
    cornea, Fundacion Hospital Nuestra Senora de la Luz I.A.P, mexico city, Mexico
  • Footnotes
    Commercial Relationships  Adriano J. Carpizo, None; Alejandro Babayan-Sosa, None; Oscar Baca-Lozada, None; Oscar Fernandez-Vizcaya, None; Simon Romano-Bucay, None; Regina Velasco-Ramos, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 373. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Adriano J. Carpizo, Alejandro Babayan-Sosa, Oscar Baca-Lozada, Oscar Fernandez-Vizcaya, Simon Romano-Bucay, Regina Velasco-Ramos; Intravenous Corticosteroid Treatment In Endothelial Corneal Allograft Rejection: Efficacy And Safety. Invest. Ophthalmol. Vis. Sci. 2011;52(14):373.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the efficacy and safety of intravenous corticosteroid treatment in endothelial corneal allograft rejection

Methods: : This is a comparative study between a control group of patients treated with topical corticosteroid 1% prednisolone acetate only, and a group of patients with an acute endothelial allograft rejection episode. (No longer than eight days) The treatment consisted in 500 mg pulsed intravenous methylprednisolone. A written consent was given. The presence of any adverse event or secondary reaction during treatment was recorded. Follow up treatment was with topical corticosteroid 1% prednisolone acetate. Efficacy of the treatment was defined as the reversal of the rejection episode if the corneal graft was clear and free of edema

Results: : Nine patients were treated with 1% topical prednisolone acetate and pulsed intravenous methylprednisolone at the diagnosis of corneal allograft rejection and 11 patients were submitted to topical treatment only. 5 patients (66%) that were submitted to pulsed steroid had a good outcome, 2 patients (22%) presented corneal graft failure, while only 6 patients (55%) that received only topical steroids resulted with clear grafts and 2 patients (18%) with graft failure. No adverse effects or secondary reactions of intravenous methylprednisolone were observed

Conclusions: : This study suggests that the use of 500 mg intravenous methylprednisolone in addition to 1% topical prednisolone acetate presents a faster recovery in symptoms and clinically in reverting corneal allograft rejection when compared to the single use of 1% topical prednisolone acetate. Even though there are problems associated with this route of administration, when safety measures are taken adverse effects are lowered

Clinical Trial: : Fundación Hospital Nuestra Señora de la Luz, IAP, 0

Keywords: cornea: clinical science • corticosteroids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×